MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54

MetaVia Inc.

Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.
Liver stiffness reduced 23.7% by Day 54 via VCTE, indicating direct hepatic effect.
Fasted glucose improved 12.3 mg/dL from baseline of 105.3 mg/dL; prediabetic subject HbA1c dropped from 6.0% to 5.5%.
No treatment-related discontinuations; GI events mild to moderate.
Plans 16-week titration studies to 48 mg and 64 mg; results expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.